Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IPF Clear all
Completed Phase 2 Interventional Results available

GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

NCT03865927
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Placebo Oral Tablet, GKT137831
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 23, 2026, 10:07 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

NCT06003426
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BMS-986278, BMS-986278 Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
40 Years and older
Enrollment
1,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
70
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 59 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional Results available

Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT03955146
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases

NCT04119115
View directory record Official record
Conditions
Lung Diseases, Interstitial, Pulmonary Fibrosis
Interventions
CT-V, Metabolites
Device · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Not applicable Interventional

Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers

NCT02929017
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
SUPPORT, Currently Available Printed Material
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
45 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 4 Interventional Results available

Study of Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT03717012
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib, Pulmonary rehabilitation program
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Danbury, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 23, 2026, 10:07 AM EDT
Completed No phase listed Observational

A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis

NCT02368340
View directory record Official record
Conditions
Hermansky Pudlak Syndrome
Interventions
Pulmonary function test, Chest CT, Sample collection
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
12 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Maywood, Illinois • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT-877 in Healthy Subjects

NCT03830125
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BBT-877, Single dose, Placebo group, BBT-877, Multiple doses
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

NCT00076635
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis, Lung Disease
Interventions
Interferon gamma-1b
Drug
Lead sponsor
InterMune
Industry
Eligibility
Not listed
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Jul 23, 2026, 10:07 AM EDT
Completed No phase listed Observational

Quality of Life in IPF - Patient and Physician Perceptions

NCT04148157
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01366209
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Pirfenidone, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

NCT00109681
View directory record Official record
Conditions
Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Iloprost Inhalation Solution (Ventavis)
Drug
Lead sponsor
Actelion
Industry
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Jul 23, 2026, 10:07 AM EDT
Not listed Early Phase 1 Interventional

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

NCT04326036
View directory record Official record
Conditions
Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia, Coronavirus Infection, Interstitial Lung Disease
Interventions
Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution, Liberase Enzyme (Roche), Sterile Normal Saline for Intravenous Use
Procedure · Device · Drug
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jul 23, 2026, 10:07 AM EDT
Recruiting Phase 3 Interventional

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

NCT07671911
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Loxahatchee Groves, Florida • Miami, Florida • Gastonia, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

NCT04720443
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NIP292 tablet, NIP292 tablets
Drug
Lead sponsor
The National Institutes of Pharmaceutical R&D Co. Ltd, China
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE

NCT02633293
View directory record Official record
Conditions
Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
Interventions
Inhaled Treprostinil
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
91
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Jul 23, 2026, 10:07 AM EDT
Active, not recruiting Phase 1 Interventional

Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis

NCT04262167
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
Interventions
Lung Spheroid Stem Cells 100 million, Lung Spheroid Stem Cells 200 million
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01254409
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PRM-151, Placebo
Biological · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Jul 23, 2026, 10:07 AM EDT
Terminated Phase 3 Interventional Results available

A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

NCT03733444
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GLPG1690, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
40 Years and older
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects

NCT03092102
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
HEC585
Drug
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional Results available

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01371305
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
BG00011, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 84 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
10
States / cities
San Francisco, California • Atlanta, Georgia • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 23, 2026, 10:07 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis

NCT01362231
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
GS-6624
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
40 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Jul 23, 2026, 10:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Families-At-risk for Interstitial Lung Disease Study

NCT03641742
View directory record Official record
Conditions
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
35 Years to 100 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Jul 23, 2026, 10:07 AM EDT